1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Synta's Merger With Madrigal Creates New Entrant In NASH Race

Moving past its late-stage clinical failure with ganetespib, Synta will combine with Madrigal to develop a Phase II-ready compound for NASH and hypercholesterolemia.

Enter another competitor in the already crowded NASH arena: troubled oncology firm Synta Pharmaceuticals Corp. and privately held Madrigal Pharmaceuticals Inc. are merging in an all-stock deal to develop a selective thyroid hormone receptor agonist for non-alcoholic steatohepatitis, as well as a pair of hypercholesterolemia indications.

Under the transaction announced April 14 and scheduled to close by the end of the third quarter, Lexington, Mass.-based Synta...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

US FDA Staff Stability Should Be A Congressional Priority, Former Chief Of Staff Says

 
• By Derrick Gingery

Lawmakers should address FDA staff upheaval and help the agency “get back on track,” former agency Chief of Staff Elizabeth Jungman said, while CBER Director Vinay Prasad told staff he is asking ex-colleagues to return to the agency.

US FDA ‘Commissioner’s Voucher’ As Public Relations Tool

 
• By Michael McCaughan

NRx Pharma is trying to capitalize on the headlines about a new US FDA hyper-fast review program, illustrating that the lack of details in the FDA’s announcement is an opening for sponsors to try to grab some attention.

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By Sue Sutter

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.

US FDA Pediatric Adcomm To Examine HPV, Flu, Dengue Vaccines: No News Is Good News?

 
• By Sue Sutter

Pediatric Advisory Committee will weigh the FDA's recommendation that routine safety monitoring continue for Merck & Co's Gardasil and Sanofi's Fluzone and Dengvaxia despite a political climate that has been unkind to vaccines.

More from North America